INNMF Stock - Amplia Therapeutics Limited
Unlock GoAI Insights for INNMF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $3.78M | $4.45M | $1.19M | $1.98M | $1.53M |
| Gross Profit | $3.57M | $4.01M | $1.12M | $1.98M | $1.53M |
| Gross Margin | 94.4% | 90.1% | 93.8% | 99.8% | 100.0% |
| Operating Income | $-6,516,148 | $-4,424,972 | $-6,188,587 | $-3,643,067 | $-2,281,153 |
| Net Income | $-6,572,031 | $-4,503,453 | $-6,242,435 | $-3,644,217 | $-2,281,153 |
| Net Margin | -173.7% | -101.1% | -524.8% | -183.7% | -148.8% |
| EPS | $-0.02 | $-0.02 | $-0.03 | $-0.03 | $-0.02 |
Amplia Therapeutics Limited, a pharmaceutical company, focuses on development of focal adhesion kinase (FAK) inhibitors for oncology and chronic fibrosis in Australia. The company's product pipeline includes AMP945, an inhibitor of FAK, for pancreatic cancer and idiopathic pulmonary fibrosis, as well as other cancers and fibrotic diseases indications, that has completed Phase I clinical trial; and AMP886 for cancer and fibrotic disease indication. It has a collaboration agreement with the Garvan Institute of Media Research in Sydney. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.
Visit WebsiteEarnings History & Surprises
INNMFEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 28, 2026 | — | — | — | — |
Q4 2025 | Nov 27, 2025 | — | $-0.00 | — | — |
Q2 2025 | May 30, 2025 | — | — | — | — |
Q4 2024 | Nov 20, 2024 | — | — | — | — |
Q3 2024 | Aug 23, 2024 | — | — | — | — |
Q2 2024 | May 30, 2024 | — | $-0.01 | — | — |
Q1 2024 | Jan 29, 2024 | — | — | — | — |
Q3 2023 | Sep 29, 2023 | — | $-0.00 | — | — |
Q2 2023 | Jun 30, 2023 | — | $-0.00 | — | — |
Q1 2023 | Mar 31, 2023 | — | $-0.01 | — | — |
Q4 2022 | Dec 31, 2022 | — | $-0.01 | — | — |
Q3 2022 | Sep 29, 2022 | — | $-0.01 | — | — |
Q2 2022 | Jun 30, 2022 | — | $-0.01 | — | — |
Q1 2022 | Mar 31, 2022 | — | $-0.01 | — | — |
Q3 2021 | Sep 29, 2021 | — | $-0.01 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-0.01 | — | — |
Q3 2020 | Sep 29, 2020 | — | $-0.00 | — | — |
Q1 2020 | Mar 31, 2020 | — | $-0.01 | — | — |
Q3 2019 | Sep 29, 2019 | — | $-0.01 | — | — |
Latest News
Frequently Asked Questions about INNMF
What is INNMF's current stock price?
What is the analyst price target for INNMF?
What sector is Amplia Therapeutics Limited in?
What is INNMF's market cap?
Does INNMF pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to INNMF for comparison